Fosamax Cost in New Jersey 2026: Alendronate Price, Insurance, and Coverage Guide

What Is Alendronate and Why Is It Prescribed?

Alendronate is a bisphosphonate that suppresses osteoclast-mediated bone resorption, slowing the net loss of bone mineral density. It is FDA-approved for postmenopausal osteoporosis, osteoporosis in men, glucocorticoid-induced osteoporosis, and Paget's disease of bone. The FDA label for alendronate sodium tablets sets the standard weekly dose for osteoporosis treatment at 70 mg orally once per week [1].

The Fracture Intervention Trial (FIT, JAMA 1998, N=2,027) showed alendronate reduced the risk of hip fracture by 47% (relative risk 0.53 to 95% CI 0.31-0.90) over 36 months compared with placebo in women with low femoral-neck bone mineral density [2]. That evidence base is why the drug remains a first-line recommendation in guidelines from the American College of Obstetricians and Gynecologists and the Endocrine Society.

The American Association of Clinical Endocrinologists (AACE) 2020 Clinical Practice Guidelines on Osteoporosis state: "Oral bisphosphonates, including alendronate, are appropriate first-line pharmacological therapy for most patients with osteoporosis based on demonstrated anti-fracture efficacy and long-term safety data" [3].

Once-weekly dosing replaced the original daily 10 mg regimen after trials confirmed equivalent efficacy with a simplified schedule, improving real-world adherence significantly [4].

How Much Does Fosamax Cost in New Jersey in 2026?

Generic alendronate 70 mg tablets cost roughly $15 per month at most New Jersey retail pharmacies in 2026 when purchased with a discount card. Brand-name Fosamax carries a Merck list price near $80 per month, but fewer than 5% of New Jersey patients pay that price because generics have been available since 2008.

The $15 cash-pay figure reflects GoodRx-negotiated prices at major New Jersey pharmacy chains including CVS, Walgreens, Rite Aid, and ShopRite. Prices vary by zip code. Patients in Newark, Jersey City, Trenton, and Camden may find prices as low as $9-$12 per month at independent pharmacies that accept discount cards. Suburban and rural counties in Burlington and Hunterdon tend to cluster around $14-$18 per month [5].

A 2022 analysis published in JAMA Internal Medicine found that bisphosphonate out-of-pocket costs are a meaningful predictor of non-adherence over 12 months, with each $10 increase in monthly cost associated with a 6.4% reduction in medication possession ratio [6]. At $15 per month, generic alendronate sits in a cost range that preserves adherence for most patients compared with branded alternatives.

The National Institutes of Health MedlinePlus drug information page for alendronate confirms that generic versions are widely available and therapeutically equivalent to Fosamax [7].

For patients without any insurance or discount program, presenting a GoodRx, RxSaver, or SingleCare coupon at the pharmacy counter typically yields the $15 price without requiring any enrollment or income documentation.

Does New Jersey Medicaid Cover Alendronate?

New Jersey Medicaid (NJ FamilyCare) covers generic alendronate on its preferred drug list with a prior authorization requirement. Prior authorization confirms the diagnosis of osteoporosis or osteopenia with documented DEXA scan results showing a T-score at or below -2.5 for osteoporosis or -1.0 to -2.5 for osteopenia with additional fracture risk factors.

Managed care organizations contracted with NJ FamilyCare, including Horizon NJ Health, Aetna Better Health of New Jersey, UnitedHealthcare Community Plan, and AmeriHealth Caritas New Jersey, each maintain their own formulary tiers, but all four cover generic alendronate. Copays for dual-eligible enrollees (Medicare-Medicaid) are typically $0-$3.65 per month under Extra Help / Low Income Subsidy rules [8].

The Centers for Medicare and Medicaid Services guidance on bisphosphonate coverage notes that Medicare Part D plans must cover at least two drugs in the bisphosphonate class, meaning Medicare beneficiaries in New Jersey have guaranteed access to at least one oral bisphosphonate at a negotiated tier-1 or tier-2 copay [9].

Patients denied prior authorization by NJ FamilyCare have the right to appeal within 20 days of the denial notice. An appeal supported by DEXA T-score documentation and a prescribing clinician's letter has a high overturn rate in New Jersey based on state Office of Administrative Law records.

The Endocrine Society Clinical Practice Guideline on Pharmacological Management of Osteoporosis provides the clinical evidence prescribers commonly use to support prior authorization letters [10].

What Do Private Insurance Plans Pay for Fosamax in New Jersey?

Most commercial insurance plans in New Jersey place generic alendronate on Tier 1 (preferred generic) with a copay of $0-$10 per month. Brand-name Fosamax typically lands on Tier 3 or Tier 4, with copays from $40-$120 per month depending on the plan design.

New Jersey ACA marketplace plans sold through Get Covered NJ are required under the Affordable Care Act to cover preventive services without cost-sharing for women aged 65 and older. The U.S. Preventive Services Task Force recommends screening for osteoporosis in women aged 65 and older, and many plans extend zero-cost-sharing treatment coverage once a qualifying diagnosis is established [11].

Employer-sponsored plans offered by large New Jersey employers in the pharmaceutical, finance, and healthcare sectors generally place alendronate at $0 copay under preventive benefit riders. Mid-size and small-group plans vary considerably. Patients should request a formulary exception in writing if their plan places alendronate above Tier 2, because clinical evidence supports its preferred-generic classification [12].

The FDA drug approval database entry for alendronate confirms the drug has been approved since 1995, which supports the argument in exception requests that it is a long-standing standard of care rather than an experimental treatment [1].

Is Compounded Alendronate Legal in New Jersey?

Compounded alendronate prepared by a 503A pharmacy is legal in New Jersey and may be available at $0 out-of-pocket through certain patient assistance programs. This option is distinct from commercially manufactured generic tablets.

Under Section 503A of the Federal Food, Drug, and Cosmetic Act, licensed compounding pharmacies may prepare alendronate for individual patients based on a valid prescription from a licensed prescriber. New Jersey-licensed 503A pharmacies must comply with both federal USP standards and New Jersey Board of Pharmacy regulations [13].

Compounded formulations are most relevant for patients who cannot tolerate the standard oral tablet due to swallowing difficulties or esophageal conditions. Because alendronate carries an FDA boxed warning regarding esophageal adverse reactions, and because patients must remain upright for 30 minutes after taking the tablet, compounded alternatives (such as effervescent or liquid formulations) serve a specific clinical niche [1].

The FDA guidance on pharmacy compounding under Section 503A clarifies that 503A compounding is patient-specific and not for large-scale distribution [14]. New Jersey does not restrict alendronate as a compound, unlike some Schedule II substances.

Patients interested in compounded alendronate should ask their prescriber to specify the reason for compounding on the prescription, as this documentation supports dispensing under 503A rules and may be required by the pharmacy. Cost through 503A programs can be $0 per month when the prescriber participates in a manufacturer-linked patient assistance arrangement.

Can I Get a Fosamax Prescription via Telehealth in New Jersey?

Telehealth prescribing of alendronate is fully legal in New Jersey. A licensed New Jersey prescriber, including physicians, nurse practitioners, and physician assistants, may evaluate a patient via synchronous audio-video telehealth, review prior DEXA scan results, and issue a prescription for alendronate electronically.

New Jersey enacted the Telehealth and Telemedicine Act (P.L. 2017, c.117), which requires commercial insurance plans to cover telehealth services at parity with in-person visits. NJ FamilyCare (Medicaid) also covers telehealth consultations for established and new patients [15].

A prescriber using telehealth to initiate alendronate should review the patient's DEXA T-score, fracture history, renal function (alendronate is contraindicated in CrCl <35 mL/min per the FDA label), calcium and vitamin D status, and any history of esophageal disease before prescribing [1].

The USPSTF recommendation on osteoporosis screening provides the evidentiary foundation clinicians reference during telehealth evaluations for women 65 and older [11].

HealthRX clinicians licensed in New Jersey can order a DEXA scan at a local imaging center before the telehealth visit or review existing results from the patient's record. Most New Jersey imaging centers return DEXA results within 24-48 hours, allowing same-week prescribing in straightforward cases.

What Discount Programs Are Available for Fosamax in New Jersey?

Several savings options can bring the cost of alendronate in New Jersey below $15 per month or to $0.

GoodRx and SingleCare. Free discount cards accepted at most New Jersey pharmacies. No enrollment, no income requirement. Typical price: $9-$15 for a 30-day supply of generic alendronate 70 mg.

NeedyMeds and RxAssist. Both databases list patient assistance programs for brand-name Fosamax through Merck's patient assistance program (Merck Helps). Eligibility typically requires income at or below 200% of the federal poverty level and lack of insurance coverage for the drug [16].

New Jersey Pharmaceutical Assistance to the Aged and Disabled (PAAD). PAAD provides drug cost assistance to New Jersey residents who are 65 or older (or receiving Social Security Disability Insurance) with income below a set threshold (updated annually by the state). Alendronate is covered under PAAD, and enrolled patients pay a flat $5 copay per prescription [17].

Senior Gold. New Jersey's Senior Gold Prescription Discount Program covers residents who exceed PAAD income limits but still need help. Alendronate is included. Copays range from $15-$30 depending on drug cost [17].

Medicare Extra Help (Low Income Subsidy). Dual-eligible New Jersey residents pay $0-$3.65 per month for alendronate under Extra Help. The Social Security Administration Extra Help program page provides current eligibility thresholds [8].

A published cost-effectiveness analysis in Annals of Internal Medicine found that oral bisphosphonate therapy for osteoporosis is cost-effective at a willingness-to-pay threshold of $50,000 per quality-adjusted life year gained, supporting the argument that payers should cover alendronate at the lowest possible patient cost tier [18].

Clinical Evidence Supporting Alendronate Use

The fracture reduction data for alendronate are among the most replicated in osteoporosis pharmacology.

FIT (Fracture Intervention Trial, JAMA 1998, N=2,027) demonstrated a 47% relative risk reduction in hip fracture (RR 0.53 to 95% CI 0.31-0.90) and a 55% reduction in radiographic vertebral fractures over 36 months [2]. These results established alendronate as the benchmark against which newer agents are compared.

The FIT Long-term Extension (FLEX) trial (JAMA 2006, N=1,099) evaluated continuing versus discontinuing alendronate after five years. Women who continued for ten years showed significantly fewer clinical vertebral fractures compared with those who stopped at five years (2.4% vs. 5.3%, P<0.001), informing current guidelines on treatment duration [19].

A Cochrane systematic review of bisphosphonates for osteoporosis (updated 2023) confirmed that alendronate reduces vertebral fracture risk by approximately 45% and non-vertebral fracture risk by approximately 16% compared with placebo, based on pooled data from 11 randomized controlled trials [20].

The Endocrine Society 2019 guideline states: "We recommend pharmacological treatment with antiresorptive or anabolic agents in postmenopausal women with osteoporosis to reduce fracture risk" and positions alendronate as a preferred first-line oral agent based on cost, availability, and evidence base [10].

The HealthRX clinical team uses a five-point checklist before initiating alendronate via telehealth in New Jersey:

1. DEXA T-score at or below -2.5 (osteoporosis) or FRAX 10-year hip fracture probability at or above 3% with T-score -1.0 to -2.5.
2. Estimated glomerular filtration rate (eGFR) above 35 mL/min/1.73m² (alendronate is contraindicated below this threshold per FDA labeling).
3. No active esophageal disease, achalasia, or stricture.
4. Calcium intake of 1,000-1 to 200 mg/day confirmed or supplemented.
5. Vitamin D 25-OH level above 20 ng/mL confirmed or supplemented to target.

This framework streamlines the prior authorization letter for NJ FamilyCare and most commercial insurers, because each point maps directly to the clinical criteria in their PA templates.

Monitoring and Safety Considerations

Alendronate is generally well tolerated when taken correctly. The most common adverse effects are gastrointestinal: esophageal irritation, heartburn, and abdominal pain. These are largely preventable by taking the tablet with a full 8-ounce glass of plain water and remaining upright for at least 30 minutes afterward, per FDA labeling [1].

Osteonecrosis of the jaw (ONJ) and atypical femoral fractures (AFF) are rare but recognized risks with long-term bisphosphonate use. The American Society for Bone and Mineral Research (ASBMR) Task Force on AFF (2016) reported an incidence of 3.2-50 cases per 100,000 person-years of bisphosphonate exposure, rising with duration beyond five years [21].

Most guidelines recommend reassessing the need for continued therapy after three to five years. A drug holiday of one to three years may be appropriate for patients at moderate fracture risk who have completed five years of oral bisphosphonate therapy, per the ASBMR 2016 task force report [21].

Renal function monitoring is recommended annually. Alendronate accumulates in bone and does not require dose reduction for mild-to-moderate renal impairment (eGFR 35-60 mL/min), but it should not be used if eGFR falls below 35 mL/min [1].

Serum calcium should be measured before initiating therapy. Hypocalcemia must be corrected prior to starting alendronate, as the drug can worsen existing hypocalcemia by reducing bone resorption and the release of calcium from bone [10].

Dental evaluation before starting therapy is advisable for patients who will need invasive dental procedures within the next 12 months, given the small but real ONJ risk during dental extractions [22].